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A commentary on
Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing
depressed mood in patients with major depression
by Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Mol Psychiatry (2015). doi:10.1038/mp.2015.53
In the past decades, almost all research in psychiatry and clinical psychology has been directed at the
level of disorders, such as major depressive disorder (MDD) or schizophrenia. As has been argued
by many scholars in recent work, this organization of the psychiatric research program has yielded
limited insights, which justifies the investigation of psychopathology at amore fine-grained level: the
level of symptoms (1, 2). In the present letter, we indicate two primary directions for this research
program, which we propose to call symptomics. We will focus our discussion on MDD specifically
and discuss possibilities in relation to the recently published work by Hieronymus et al. (3).
Firstly, research has now shown that distinct depression symptoms, such as sadmood or insomnia
differ in the risk factors that predispose them (4, 5), their underlying biology (6, 7), their response to
specific life events (8, 9), and their impact on impairment of psychosocial functioning (10, 11) [for
a review, see Ref. (1)]. This presents the first direction of the research agenda: to further investigate
the properties in which individual symptoms differ from each other. The recently published work by
Hieronymus et al. (3), “Consistent superiority of selective serotonin reuptake inhibitors over placebo
in reducing depressed mood in patients with major depression”, adds the differential reactivity of
depression symptoms to antidepressant medication to the prior body of work. In their analysis
of clinical trial data of 6,669 patients with MDD published in Molecular Psychiatry, the authors
document that depressive symptoms responded differentially to treatment with selective serotonin
reuptake inhibitor (SSRI) antidepressants. Pooled effect sizes ranged from 0 (for symptoms, such as
gastrointestinal and genital symptoms) to 0.44 (for depressedmood, a core symptom of depression).
Hieronymus et al. (3) argue that these findings are consistent with prior antidepressant research that
found differential treatment effects on symptoms and stress the importance of analyzing individual
depression symptoms in future studies.We would like to extend their claim: these results, along with
previous symptom-based findings, mandate the examination of symptom-specific effects throughout
the realm of psychopathology.
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FIGURE 1 | Network of 17 HRSD depression symptoms. Green lines represent positive associations, red lines negative associations, and thickness and
brightness of an edge indicate the strength of the association.
The second research direction is the investigation of distinct
patterns of causes and effects in which symptoms operate. Net-
work analysis provides a tool to investigate these specific associ-
ations between symptoms that can sustain mental disorders (2).
Contrasting the traditional explanation that the co-occurrence
of symptoms (such as the depressive syndrome) is due to one
underlying shared origin (MDD causes depression symptoms),
networks conceptualize depression as a complex dynamic system
of mutually reinforcing associations (12, 13). Figure 1 presents an
example of such a psychopathological network – in the form of a
Markov random field (MRF) – for the Hamilton Depression Rat-
ing Scale (HRSD), the same instrument analyzed by Hieronymus
et al. (3).We computed the network from the enrollment symptom
data of 3,467 patients from the antidepressant trial “sequenced
treatment alternatives to relieve depression” (STAR*D) (14), a
dataset that can be requested at the NIMH. The network can be
viewed as a tentative estimate of the causal skeleton of a disorder
and may be used to gauge which symptoms are most central in
receiving input, and/or sending out influences into the system
(15). Applying a network perspective to the paper by Hieronymus
et al. (3) gains considerable analytic power. For example, the
centrality of the STAR*D HRSD symptoms, as measured by their
closeness to other symptoms in the network (2), correlates r= 0.53
(p< 0.05) with the symptom effect sizes reported by the authors.
This means that more central symptoms exhibit greater reactivity
to the intervention. In addition, symptomswith a higher closeness
have a higher reported baseline severity (r= 0.60, p< 0.05) and
symptoms with a higher baseline severity exhibit a (much) larger
effect size (r= 0.77, p< 0.001). Thus, an interesting three-way
pattern arises with more central HRSD items exhibiting higher
reported means and higher reported reactivity to interventions.
While we can only speculate as to what produces this intriguing
pattern of effects, the most important message is that focusing on
the level of symptoms and analyzing the causal relations among
them is likely to extend our understanding of psychopathology
directly and significantly. The widespread reliance on disorders
and the associated focus on symptom sum-scores in investi-
gations of the biology and treatment of psychopathology may
have concealed crucial insights (1, 16). A number of multivariate
approaches have been developed for, and used with, depression
symptoms previously, including structural equation models and
network analyses (4, 9); in addition, time-series analysis studying
network dynamics has become available as a tool to zoom in on
the micro-level interactions among symptoms (17). Paying close
attention to symptoms and their dynamics may have important
clinical implications. Due to the highly heterogeneous nature of
MDD (18, 19), individuals may differ substantially from each
other not only in the symptoms they exhibit, but also in the way
their symptoms are related to contextual influences, and in the
way symptoms shape each other across time. A treatment focus on
especially prevalent and central symptoms, instead of the categori-
cally defined and heterogeneous disorders itself,may help increase
the currently disappointing levels of treatment response (20). A
broader investigation of symptom-specific treatment effects sim-
ilar to the study performed by Hieronymus et al. (3) would enable
clinical trials to match participants to specific treatments, based
on their symptom profiles and dynamics.
In summary, symptomics invites the application of new mod-
eling efforts to the level of individual symptoms as fundamental
building blocks of mental disorders. As such, it may herald a time
of renewed research energy that could, finally, provide an inroad
to achieve real understanding of the mechanisms underlying
psychopathology.
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